scholarly journals Magnetic resonance imaging - ultrasound fusion targeted biopsy outperforms standard approaches in detecting prostate cancer: A meta-analysis

2016 ◽  
Vol 5 (2) ◽  
pp. 301-309 ◽  
Author(s):  
Xuping Jiang ◽  
Jiayi Zhang ◽  
Jingyuan Tang ◽  
Zhen Xu ◽  
Wei Zhang ◽  
...  
2019 ◽  
Vol 104 (3-4) ◽  
pp. 187-198 ◽  
Author(s):  
Xiang Tu ◽  
Zhenhua Liu ◽  
Chichen Zhang ◽  
Tiancong Chang ◽  
He Xu ◽  
...  

2019 ◽  
Vol 76 (3) ◽  
pp. 284-303 ◽  
Author(s):  
Veeru Kasivisvanathan ◽  
Armando Stabile ◽  
Joana B. Neves ◽  
Francesco Giganti ◽  
Massimo Valerio ◽  
...  

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 70-70
Author(s):  
Xiang Tu ◽  
Zhenhua Liu ◽  
Shi Qiu ◽  
He Xu ◽  
Jiakun Li ◽  
...  

70 Background: Magnetic Resonance Imaging-Transrectal Ultrasound (MRI/TRUS) fusion targeted biopsy (TB) has been demonstrated to increase detection rates (DRs) of prostate cancer (PCa) in repeat-biopsy setting. However, its role in biopsy-naïve men remains controversial. We performed a meta-analysis based on well-designed randomized controlled trials (RCTs) to compare the diagnostic accuracy of MRI/TRUS fusion TB and systematic biopsy (SB) in the detection of PCa in biopsy-naïve men. Methods: A systematic review of PubMed (Medline), Embase, Ovid and the Cochrane Library up to 1st October, 2018 was conducted. The statistical analyses were performed with Revman 5.3. We compared the diagnostic accuracy between the intervention group (assisted with fusion TB) and the control group (SB only) by calculating the risk ratio (RR) with 95% confidence intervals (CIs) of overall PCa and clinically significant PCa (csPCa) DRs. Subgroup analysis was performed to highlight the independent role of MRI/TRUS fusion TB alone or combining fusion TB and SB together in the detection of PCa. Results: Six RCTs with 2187 participants were evaluated for the DRs of overall PCa. Pooled analysis revealed slight higher DRs of 62.7% (687/1095) in the intervention group compared with that of 41.3% (451/1092) in the control group (RR 1.40, 95% CI: 1.00-1.95). Four studies with 962 participants were evaluated for the DRs of csPCa. There is a trend favoring the intervention group which detected more csPCa (42.8%, 206/481) compared with SB in the control group (31.6%, 152/481) but with no significant difference (RR 1.36, 95% CI: 0.95-1.95). Subgroup analysis revealed fusion TB alone with less biopsy cores may equal the DRs of csPCa compared with SB alone (RR 1.24, 95% CI: 0.79-1.93). However, the DRs of overall PCa when combining MRI/TRUS fusion TB and SB was comparable to that applying SB alone (RR 1.48, 95% CI: 0.99-2.22). Conclusions: MRI/TRUS fusion TB may obtain similar csPCa DRs with less biopsy cores. But currently there was no enough evidence showing fusion TB can help significantly improve overall PCa or csPCa DRs compared with SB alone in biopsy-naïve men.


Sign in / Sign up

Export Citation Format

Share Document